Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Atropine,Pralidoxime Chloride
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : U.S. Department of Health and Human Services
Deal Size : $129.0 million
Deal Type : Funding
Kindeva Secures $129M SNS Contract for Nerve Agent Antidote
Details : The funding aims to advance the the manufacturing of DuoDote (atropine and pralidoxime chloride). It is indicated for the treatment of poisoning by organophosphorus nerve agents.
Product Name : Duodote
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 16, 2025
Lead Product(s) : Atropine,Pralidoxime Chloride
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : U.S. Department of Health and Human Services
Deal Size : $129.0 million
Deal Type : Funding
Nutriband Signs Agreement with Kindeva for Abuse Deterrent Fentanyl Patch
Details : Kindeva will develop commercial manufacturing processes and clinical supplies for Aversa Fentanyl, integrating Nutriband's AVERSA™ abuse-deterrent technology with Kindeva's fentanyl patch system.
Product Name : Aversa Fentanyl
Product Type : Controlled Substance
Upfront Cash : Undisclosed
May 01, 2024
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Sandoz B2B
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Albuterol sulfate is used to treat or prevent bronchospasm in patients four years and older with reversible obstructive airway disease, such as asthma, and to prevent exercise-induced bronchospasm.
Product Name : Proventil HFA
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 16, 2021
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Sandoz B2B
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : BOL-DP-o-04
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Bol Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Kindeva and BOL Pharma Sign Agreement for Development of Inhaled Cannabinoid Products
Details : Under the agreement, Kindeva will develop novel formulations of BOL Pharma’s cannabinoid based drug products delivered by Kindeva’s metered-dose inhaler (MDI) technology.
Product Name : BOL-DP-o-04
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 12, 2020
Lead Product(s) : BOL-DP-o-04
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Bol Pharma
Deal Size : Undisclosed
Deal Type : Agreement